Medpace (MEDP) Stock Forecast, Price & News

Medpace (NASDAQ:MEDP) Frequently Asked Questions

Is Medpace a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medpace stock.
View analyst ratings for Medpace or view top-rated stocks.

Are investors shorting Medpace?

Medpace saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,650,000 shares, an increase of 24.1% from the April 30th total of 1,330,000 shares. Based on an average daily volume of 313,600 shares, the short-interest ratio is currently 5.3 days. Currently, 6.0% of the shares of the stock are short sold.
View Medpace's Short Interest.

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Monday, July 25th 2022.
View our earnings forecast for Medpace.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) issued its earnings results on Monday, April, 25th. The company reported $1.69 EPS for the quarter, beating analysts' consensus estimates of $1.26 by $0.43. The business earned $330.90 million during the quarter, compared to analysts' expectations of $327.09 million. Medpace had a trailing twelve-month return on equity of 24.17% and a net margin of 16.47%. The company's quarterly revenue was up 27.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.17 EPS.
View Medpace's earnings history.

What guidance has Medpace issued on next quarter's earnings?

Medpace updated its FY22 earnings guidance on Monday, April, 25th. The company provided earnings per share guidance of $5.72-6.06 for the period, compared to the consensus earnings per share estimate of $5.85. The company issued revenue guidance of $1.40-1.46 billion, compared to the consensus revenue estimate of $1.41 billion.

What price target have analysts set for MEDP?

3 analysts have issued 1 year price targets for Medpace's shares. Their forecasts range from $167.90 to $205.00. On average, they expect Medpace's stock price to reach $182.63 in the next twelve months. This suggests a possible upside of 23.9% from the stock's current price.
View analysts' price targets for Medpace or view top-rated stocks among Wall Street analysts.

Who are Medpace's key executives?

Medpace's management team includes the following people:

• Dr. August James Troendle M.D., Chairman & CEO (Age 66, Pay $1.54M)
• Mr. Jesse J. Geiger BBA, CPA, Pres (Age 48, Pay $805.42k) (LinkedIn Profile)
• Mr. Kevin M. Brady, CFO & Treasurer (Age 48, Pay $547.17k) (LinkedIn Profile)
• Ms. Susan E. Burwig, Exec. VP of Operations (Age 59, Pay $910.29k) (LinkedIn Profile)
• Mr. Stephen P. Ewald, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 53, Pay $753.98k) (LinkedIn Profile)
• Brandon Ebken, Chief Information Officer
• Ms. Lauren Morris, Associate Director of Investors Relations
• Mr. Todd Meyers, VP of Bus. Devel. & Marketing
• Mr. Weimin Gai MS, Sr. VP of Biometrics
• Mr. Daniel O'Leary, Sr. VP of Medical Department

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace CEO August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among Medpace's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Medpace's key competitors?

Some companies that are related to Medpace include ICON Public (ICLR), Incyte (INCY), Bitcoin Group (BTGGF), Charles River Laboratories International (CRL), Syneos Health (SYNH), SomaLogic (SLGC), National Research (NRC), MaxCyte (MXCT), Science 37 (SNCE), Inotiv (NOTV), Absci (ABSI), Starpharma (SPHRY), Luna Innovations (LUNA), Zymergen (ZY) and Auxly Cannabis Group (CBWTF).
View all of MEDP's competitors.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.27%), Vanguard Group Inc. (9.30%), Wasatch Advisors Inc. (8.11%), State Street Corp (2.67%), Invesco Ltd. (2.66%) and Echo Street Capital Management LLC (2.07%). Company insiders that own Medpace stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends for Medpace.

Which institutional investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Polen Capital Management LLC, Invesco Ltd., First Trust Advisors LP, Meritage Portfolio Management, Vanguard Group Inc., Russell Investments Group Ltd., and Assenagon Asset Management S.A.. Company insiders that have sold Medpace company stock in the last year include Ashley M Keating, August J Troendle, Kevin M Brady, Medpace Investors, Llc, Stephen P Ewald, Susan E Burwig, and Tom C King.
View insider buying and selling activity for Medpace or view top insider-selling stocks.

Which institutional investors are buying Medpace stock?

MEDP stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Boston Trust Walden Corp, Echo Street Capital Management LLC, Grandeur Peak Global Advisors LLC, BlackRock Inc., Riverbridge Partners LLC, Woodline Partners LP, and Raymond James & Associates. Company insiders that have bought Medpace stock in the last two years include Peter J O'malley, and Wedbush Securities Inc.
View insider buying and selling activity for Medpace or or view top insider-buying stocks.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $147.37.

How much money does Medpace make?

Medpace has a market capitalization of $4.96 billion and generates $1.14 billion in revenue each year. The company earns $181.85 million in net income (profit) each year or $5.36 on an earnings per share basis.

How many employees does Medpace have?

Medpace employs 4,500 workers across the globe.

What is Medpace's official website?

The official website for Medpace is www.medpace.com.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at (513) 579-9911, via email at [email protected], or via fax at 513-579-0444.